{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.104","upperLimit":"0.456","value":"0.25"},{"groupId":"OG001","lowerLimit":"0.274","upperLimit":"0.680","value":"0.47"},{"groupId":"OG002","lowerLimit":"0.351","upperLimit":"0.756","value":"0.56"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"description":"ORR was defined as the proportion of participants achieving complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.","dispersionType":"90% Confidence Interval","groups":[{"description":"* Participants will receive eribulin intravenously on Day 1 and Day 8\n* Pembrolizumab is administered intravenously Day 1, on a 21-day cycle\n\nEribulin: The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).\n\nPembrolizumab: The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.","id":"OG000","title":"Liposarcomas"},{"description":"* Participants will receive eribulin intravenously on Day 1 and Day 8\n* Pembrolizumab is administered intravenously Day 1, on a 21-day cycle\n\nEribulin: The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).\n\nPembrolizumab: The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.","id":"OG001","title":"Leiomyosarcomas"},{"description":"* Participants will receive eribulin intravenously on Day 1 and Day 8\n* Pembrolizumab is administered intravenously Day 1, on a 21-day cycle\n\nEribulin: The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).\n\nPembrolizumab: The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.","id":"OG002","title":"Undifferentiated Pleomorphic Sarcomas"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Objective Response Rate(ORR)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}